Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report databases, and the role of pharmacists
This study provides robust evidence of the bleeding risks associated with antiplatelet therapies across diverse clinical settings, emphasizing the need for heightened clinical vigilance. Furthermore, it highlights the critical role of pharmacists in optimizing antiplatelet therapy management and reducing bleeding complications.
Authors
- Kaili Mao (ORCID: https://orcid.org/0009-0001-1556-4365)
- Liucheng Li (ORCID: https://orcid.org/0000-0002-2511-0156)
- Zhihui Zhang (ORCID: https://orcid.org/0000-0003-3111-2665)
- Feng Xu (ORCID: https://orcid.org/0000-0001-6215-8696)
- Miaomiao Chen (ORCID: https://orcid.org/0000-0002-6984-5787)
Institutions
- Wenzhou Medical University (CN)
- Ruijin Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Quzhou City People's Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Ningbo No. 2 Hospital (CN)
- Zero to Three (US)
- Quzhou University (CN)
- Ningbo No.6 Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1097/js9.0000000000003667
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.31